Antiviral drug-induced nephrotoxicity

被引:339
作者
Izzedine, H [1 ]
Launay-Vacher, V [1 ]
Deray, G [1 ]
机构
[1] Hop La Pitie Salpetriere, Dept Nephrol, F-75013 Paris, France
关键词
tubular dysfunction; renal failure; nephrotoxicity; antiviral drugs;
D O I
10.1053/j.ajkd.2005.02.010
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Drug-induced kidney injury is a major side effect in clinical practice, frequently leading to acute renal failure (ARF). It accounts for more than 2% to 15% of cases of ARF in patients admitted to the hospital or in the intensive care unit, respectively. The exact frequency of nephrotoxicity induced by antiviral drugs is difficult to determine. Antiviral drugs cause renal failure through a variety of mechanisms. Direct renal tubular toxicity has been described with a number of new medications with unique effects on epithelial cells of the kidney. These include cidofovir, adefovir dipivoxil, and tenofovir, as well as acyclovir. Additionally, crystal deposition in the kidney may promote the development of renal failure. Several different drugs have been described to induce crystal nephropathy, including acyclovir and the protease inhibitor indinavir. Renal injury associated with antiviral drugs involves diverse processes having effects on the renal transporters, as well as on tubule cells. In this article, we review the pathogenesis of antiviral drug-induced kidney injury, common nephrotoxic renal syndromes, and strategies for preventing kidney injury.
引用
收藏
页码:804 / 817
页数:14
相关论文
共 113 条
[1]   ACUTE RENAL-FAILURE DURING THERAPY WITH RECOMBINANT HUMAN GAMMA-INTERFERON [J].
AULT, BH ;
STAPLETON, FB ;
GABER, L ;
MARTIN, A ;
ROY, S ;
MURPHY, SB .
NEW ENGLAND JOURNAL OF MEDICINE, 1988, 319 (21) :1397-1400
[2]   ACUTE INTERSTITIAL NEPHRITIS WITH THE NEPHROTIC SYNDROME FOLLOWING RECOMBINANT LEUKOCYTE-A INTERFERON THERAPY FOR MYCOSIS-FUNGOIDES [J].
AVERBUCH, SD ;
AUSTIN, HA ;
SHERWIN, SA ;
ANTONOVYCH, T ;
BUNN, PA ;
LONGO, DL .
NEW ENGLAND JOURNAL OF MEDICINE, 1984, 310 (01) :32-35
[3]  
Bach MC, 1997, J ACQ IMMUN DEF SYND, V14, P296
[4]   Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults [J].
Barditch-Crovo, P ;
Deeks, SG ;
Collier, A ;
Safrin, S ;
Coakley, DF ;
Miller, M ;
Kearney, BP ;
Coleman, RL ;
Lamy, PD ;
Kahn, JO ;
McGowan, I ;
Lietman, PS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (10) :2733-2739
[5]   ADVERSE-EFFECTS OF HIGH-DOSE INTRAVENOUS ACYCLOVIR IN AMBULATORY PATIENTS WITH ACUTE HERPES-ZOSTER [J].
BEAN, B ;
AEPPLI, D .
JOURNAL OF INFECTIOUS DISEASES, 1985, 151 (02) :362-365
[6]   FOSCARNET AND CRYSTALS IN GLOMERULAR CAPILLARY LUMENS [J].
BEAUFILS, H ;
DERAY, G ;
KATLAMA, C ;
DOHIN, E ;
HENIN, D ;
SAZDOVITCH, V ;
JOUANNEAU, C .
LANCET, 1990, 336 (8717) :755-755
[7]   Drug-induced diabetes insipidus - Incidence, prevention and management [J].
Bendz, H ;
Aurell, M .
DRUG SAFETY, 1999, 21 (06) :449-456
[8]   Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study [J].
Benhamou, Y ;
Bochet, M ;
Thibault, V ;
Calvez, V ;
Fievet, MH ;
Vig, P ;
Gibbs, CS ;
Brosgart, C ;
Fry, J ;
Namini, H ;
Katiama, C ;
Poynard, T .
LANCET, 2001, 358 (9283) :718-723
[9]   Reconsidering targeted toxins to eliminate HIV infection: You gotta have HAART [J].
Berger, EA ;
Moss, B ;
Pastan, I .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (20) :11511-11513
[10]  
BERNS JS, 1991, J AM SOC NEPHROL, V1, P1061